JBI-802, novel dual inhibitor of LSD1-HDAC6 for treatment of cancer

被引：10
|
作者：
Sivanandhan, Dhanalakshmi [1 ]
Rajagopal, Sridharan [1 ]
Nair, Sreekala [2 ]
Basavaprabhu, B. [2 ]
Dhkar, Reshma [2 ]
Viswakarma, Santosh [2 ]
Siddiqui, Amir [2 ]
Zainuddin, Mohd [2 ]
Rudresh, G. [2 ]
Daram, Prashanthi [2 ]
Mohire, Sunil [2 ]
Krishnakumar, V [2 ]
机构：
[1] Jubilant Therapeut Ltd, Yardley, PA USA
[2] Jubilant Biosys Ltd, Bangalore, Karnataka, India
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-1756
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1756
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Novel Dual Inhibitor of LSD1-HDAC6/8 for Treatment of Cancer
    Dhanalakshmi, S.
    Rajagopal, Sridharan
    Sadhu, Naveen
    Chandru, G.
    Siddiqui, Amir
    Wahid, Saif
    Prabhu, Basava
    Neha, K. S.
    Nair, Sreekala
    Rudresh, G.
    Daram, Prasanthi
    Zainuddin, Mohd
    Tantry, Subramanyam J.
    Thiagaraj, Dinesh
    Krishnakumar, V
    Vishwakarma, Santosh
    BLOOD, 2020, 136
  • [2] LSD1-HDAC6 dual inhibitor JBI-802 is an epigenetic modulating agent with a novel mechanism of action that target MYC amplification in multiple neuroendocrine tumor types.
    Sivanandhan, Dhanalakshmi
    Rajagopal, Sridharan
    Gajendran, Chandru
    Sadhu, Naveen
    Zainuddin, Mohd
    Gosu, Ramachandraiah
    Rastelli, Luca
    CANCER RESEARCH, 2022, 82 (23)
  • [3] JBI-802: the first orally available LSD1/HDAC6 dual inhibitor to enter clinical trials
    Zhang, Jingya
    Ren, Xiangli
    Song, Yihui
    Yu, Bin
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2025,
  • [4] Novel dual inhibitors of LSD1-HDAC6/8 for treatment of cancer
    Sivanandhan, Dhanalakshmi
    Rajagopal, Sridharan
    Nair, Sreekala
    Gajendran, Chandru
    Ghosh, Dimpy
    Nagaraj, P.
    Tantry, Subramanyam J.
    Dewang, Purushottam
    Hallur, Mahanandeesha S.
    Murugan, Kannan
    Srinatha, K. C.
    Kuntrapaku, Damodara
    Dilipkumar, M.
    Sharma, R.
    Meghashree, S.
    Kumar, Durga Prasanna
    Ingle, Suraj P.
    Zainuddin, Mohd
    Vinod, A. B.
    Rajagopal, Sriram
    CANCER RESEARCH, 2019, 79 (13)
  • [5] Novel dual inhibitors of LSD1-HDAC6/8 for treatment of cancer
    Dhanalakshmi, Sivanandhan
    Rajagopal, Sridharan
    Nair, Sreekala
    Gajendran, Chandru
    Ghosh, Dimpy
    Tantry, Subramanyam Janardhan
    Dewang, Purushottam
    Hallur, Mahanandeesha
    Kannan, M.
    Srinatha, K. C.
    Kuntrapaku, Damodara
    Dilipkumar, M.
    Sharma, Radha
    Meghashree, S.
    Kumar, D. P.
    Zainuddin, Mohd
    Vinod, A. B.
    Rajagopal, Sriram
    CANCER RESEARCH, 2018, 78 (13)
  • [6] Novel dual LSD1/HDAC6 inhibitor for the treatment of cancer
    Gajendran, Chandru
    Tantry, Subramanyam Janardhan
    Sadhu, M. Naveen
    Mohammed, Zainuddin
    Dewang, Purushottam
    Hallur, Mahanandeesha
    Nair, Sreekala
    Vaithilingam, Krishnakumar
    Nagayya, Basavaprabhu
    Rajagopal, Sridharan
    Sivanandhan, Dhanalakshmi
    PLOS ONE, 2023, 18 (01):
  • [7] Novel dual inhibitors of LSD1-HDAC for treatment of cancer
    Sivanandhan, Dhanalakshmi
    Rajagopalan, Sridharan
    Nair, Sreekala
    Dewang, Purushottam
    Kumar, Durga Prasanna
    Mulakala, Chandrika
    Mahadevan, Lavanya
    Skariah, Neema
    Kavuru, Venkata Giri
    Kuntrapaku, Damodara
    Sajja, Suchitra
    Zainuddin, Mohammad
    Krishnakumar, V
    Singh, Ritu
    Swarnakumari, V
    Gosu, Ramachandraiah
    Aiyar, Jayashree
    Iyer, Pravin
    Rajagopal, Sriram
    CANCER RESEARCH, 2015, 75
  • [8] Novel dual LSD1/HDAC6 inhibitors for the treatment of multiple myeloma
    Sadhu, M. Naveen
    Sivanandhan, Dhanalakshmi
    Gajendran, Chandru
    Tantry, Subramanyam
    Dewang, Purushottam
    Murugan, Kannan
    Chickamunivenkatappa, Srinatha
    Zainuddin, Mohd
    Nair, Sreekala
    Vaithilingam, Krishnakumar
    Rajagopal, Sridharan
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2021, 34
  • [9] Discovery of a novel AR/HDAC6 dual inhibitor for prostate cancer treatment
    Zhou, Maojun
    Zheng, Hao
    Li, Yubin
    Huang, Huichao
    Min, Xiaoli
    Dai, Shuyan
    Zhou, Wenqiang
    Chen, Zhuchu
    Xu, Guangyu
    Chen, Yongheng
    AGING-US, 2021, 13 (05): : 6982 - 6998
  • [10] Dual HDAC and LSD1 inhibition as a novel strategy to overcome BRAF inhibitor resistance
    Gibson, F.
    Hanly, A.
    Kuang, K.
    Kalin, J.
    Wu, M.
    Cole, P.
    Alani, R.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (07) : S89 - S89
12345